 Double-blind placebo-controlled cross-over trial progabide add-on therapy epileptic patients double-blind cross-over trial progabide PGB placebo add-on therapy patients moderate epilepsy patients study adverse drug reactions elevation liver transaminases gastritis psychosis administrative reasons patients seizure frequency patients PGB treatment patients placebo number days seizures PGB treatment patients physicians preferences end trial favor PGB Mild clinical side effects present patients PGB placebo Increase liver transaminases patients double-blind study follow-up period data PGB useful patients antiepileptic drugs AEDs compound liver function